Physician profile
Michael Vickers
NPI 1427057371
$2,894.81
in general payments reported to CMS, 2019-2025
27 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $111 · 2021: $296 · 2022: $307 · 2023: $253 · 2024: $1,250 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Travel and Lodging: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.23 |
| Travel and Lodging | $544.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $829.54 | 2024-2025 | Percept Pc Brainsense |
| Abbvie INC. | $581.35 | 2022-2025 | Botox, Ubrelvy, Duopa |
| Eisai INC. | $385.78 | 2024-2025 | |
| Biogen, INC. | $172.58 | 2021 | |
| Ucb, INC. | $124.54 | 2022-2025 | Fintepla, Zilbrysq |
| Radius Health, INC. | $100.00 | 2019 | |
| Argenx US, INC. | $74.20 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $70.11 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $63.39 | 2020-2021 | |
| Lundbeck LLC | $53.94 | 2023-2024 | Vyepti, Rexulti |
| Sunovion Pharmaceuticals INC. | $52.78 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $50.74 | 2020-2025 | |
| Neurelis, INC. | $37.91 | 2024-2025 | Valtoco |
| Amgen INC. | $37.07 | 2019-2021 | |
| Sk Life Science, INC. | $34.79 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.72 | 2022 | |
| Allergan, INC. | $26.41 | 2019-2020 | |
| Genzyme Corporation | $24.62 | 2020 | |
| Alexion Pharmaceuticals, INC. | $22.59 | 2023 | Ultomiris |
| Amneal Pharmaceuticals LLC | $19.88 | 2024 | Rytary |
| Octapharma USA, INC. | $18.10 | 2021 | |
| Pfizer INC. | $17.72 | 2024 | |
| Genentech USA, INC. | $16.78 | 2020 | |
| Ge Healthcare | $13.72 | 2019 | |
| Acadia Pharmaceuticals INC | $13.63 | 2023 | Nuplazid |
| Zyla Life Sciences, INC. | $11.20 | 2020 | |
| Emd Serono, INC. | $10.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.